|Bid||0.00 x 1200|
|Ask||0.00 x 900|
|Day's Range||47.82 - 48.82|
|52 Week Range||45.58 - 59.00|
|Beta (5Y Monthly)||0.22|
|PE Ratio (TTM)||19.00|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
HILDEN, Germany & GERMANTOWN, Maryland, January 10, 2022--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced important enhancements in the commercialization of its QIAstat-Dx syndromic testing solution – which enables laboratories and hospitals worldwide to test patients for multiple pathogens from one sample – with new tests and the launch of a higher-throughput version that includes a new level of walk-away efficiency through the new QIAstat-Dx Smart Drawer.
HILDEN, Germany & GERMANTOWN, Md., January 07, 2022--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new additions to the growing number of applications for QIAcuity, its ultrasensitive digital PCR (dPCR) platform that has set new standards by using so-called nanoplates to process samples in two hours rather than the five hours required by other systems.
HILDEN, Germany & GERMANTOWN, Md., January 06, 2022--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced important expansion initiatives for its QuantiFERON franchise, building on its status as the gold standard for detection of tuberculosis, while developing new applications for this technology designed to detect potentially deadly latent diseases.